CB1 inverse agonist posts cleaner GI profile than oral GLP-1s at 5% weight loss — whether Phase 2 scales that signal decides the obesity bet

Corbus Pharmaceuticals is a clinical-stage pharmaceutical company developing an oral drug candidate for obesity that is not yet approved.

CRB-913, a peripherally restricted oral CB1 inverse agonist, posted statistically significant 5% mean weight loss at 60 mg in a 254-patient double-blind Phase 1b trial with GI tolerability markedly better than oral semaglutide, a meaningful differentiator in a crowded obesity field. The thesis resolves on whether Phase 2 monotherapy data, pending FDA engagement on the clinical plan, replicates and extends that efficacy signal at scale. The primary risk is that 5% weight loss at 12 weeks trails the double-digit losses that have set market expectations, leaving CRB-913 commercially marginal even if Phase 2 succeeds, while $118M against $36M quarterly burn funds the company only into 2028, well short of any Phase 2 readout.